Filed Pursuant to Rule 433
Registration Statement 333-223221
Dated March 25, 2020
Pfizer Inc.
Pricing Term Sheet
| Issuer: | Pfizer Inc.
|
| Security: | 2.625% Notes due 2030
|
| Principal Amount: | $1,250,000,000 aggregate principal amount
|
| Maturity Date: | April 1, 2030
|
| Coupon: | 2.625%annually, accruing from and includingMarch 27, 2020
|
| Interest Payment Dates: | April 1 and October 1 of each year, beginning on October 1, 2020
|
| Price to Public: | 99.650% of principal amount
|
| Benchmark Treasury: | 1.500% due February 15, 2030
|
| Benchmark Treasury Price and Yield: | 106-16; 0.815%
|
| Spread to Benchmark Treasury Yield: | T+185 bps
|
| Yield to Maturity: | 2.665%
|
| Optional Redemption: | The notes will be redeemable, in whole or in part, at any time and from time to time prior to January 1, 2030 (three months prior to the maturity date), at Pfizer Inc.’s option, at a redemption price equal to the greater of the following amounts: (i) 100% of the principal amount of the notes being redeemed on the redemption date; and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the notes being redeemed on that redemption date (not including the amount, if any, of accrued and unpaid interest to, but excluding, the redemption date) discounted to the redemption date on a semi-annual basis at the Treasury Rate (as defined in the prospectus supplement), as determined by the Independent Investment Banker (as defined in the prospectus supplement), plus 30 bps; plus accrued and unpaid interest on the notes being redeemed, to, but excluding, the redemption date.
At any time on or after January 1, 2030 (three months prior to the maturity date), the notes will be redeemable, in whole or in part, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus in each case, accrued and unpaid interest on the notes being redeemed to, but excluding, the redemption date.
|
| Denominations: | Minimum of $2,000 principal amount and integral multiples of $1,000 in excess of $2,000
|
| Day Count Convention: | Actual/360
|
| Expected Settlement Date: | March 27, 2020 (T+2)
|
| CUSIP/ISIN: | 717081 EW9 / US717081EW90
|
1
Expected Ratings (Moody’s/S&P)*:
| A1/AA- |
| Joint Book-Running Managers: | BofA Securities, Inc. Credit Suisse Securities (USA) LLC Morgan Stanley & Co. LLC
|
| Senior Co-Managers: | Deutsche Bank Securities Inc. RBC Capital Markets, LLC
|
| Co-Managers: | BNP Paribas Securities Corp. Standard Chartered Bank Academy Securities, Inc. Siebert Williams Shank & Co., LLC Samuel A. Ramirez & Company, Inc. |
*Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
The issuer has filed a registration statement (including a prospectus and a prospectus supplement) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site atwww.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and prospectus supplement if you request it by calling (i) BofA Securities, Inc. toll-free at (800) 294-1322, (ii) Credit Suisse Securities (USA) LLC (800) 221-1037 or (iii) Morgan Stanley & Co. LLC toll free at (866) 718-1649.
This pricing term sheet supplements the preliminary form of prospectus supplement issued by Pfizer Inc. on March 25, 2020 relating to its Prospectus dated February 26, 2018.
2
